Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

Labcorp (LH) announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the ...

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire ...

Another protein, hyperphosphorylated tau (pTau), also accumulates as toxic neurofibrillary tangles. Together, amyloid-β plaques and pTau tangles result in brain damage, neuroinflammation and ...

They tested [PtAu 8 (PPh 3) 8]-H[PMo 12 O 40], referred to as PtAu 8-PMo 12, using rapid X-ray absorption measurements and theoretical calculations. Their findings indicate that the dimensions of ...

NEWTON, Mass. - Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), currently trading near its 52-week low at $1.08 per share, has shared updates on its Alzheimer’s disease clinical program, including ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide ...